Arthritis, Tendonitis, Gout, Radiculopathy, Muscle Spasms, Synovitis, Migraine, Headache
Conditions
Brief summary
A 24-week observational prospective study on the efficacy of topical non-steroidal anti-inflammatory drugs for the relief of pain.
Detailed description
Objectives The primary objective is the change in pain levels as measured by a 10-point visual analog scale (VAS). Secondary objectives are changes in concomitant pain medication use, quality of life, and patient satisfaction with pain management. Design and Outcomes The study will be conducted at 1 family practice medical clinic in Houston, TX. Patients will be prescribed a pain cream compound based on their symptoms and medical history. Periodic surveys will be administered and concomitant medications recorded to ascertain current pain levels, quality of life, and satisfaction with current pain levels. Blood tests will be performed to monitor liver and kidney function. Interventions and Duration Non-steroidal anti-inflammatory steroid (NSAID) topical cream will be prescribed to patients presenting with pain. For patients with localized pain, they will also be prescribed a transdermal analgesic patch to wear at the site of pain. Subjects will be followed for 24-weeks with surveys administered at baseline, and 1, 2, 4, 8, 12, 16, 20, and 24-weeks after baseline with blood tests performed at 12 and 24-weeks. If patients do not find satisfactory pain relief or experience undesirable side effects from the cream they will be given a prescription for an oral NSAID at anytime during the 24-week observation. Sample Size and Population 500 patients will be enrolled in the study between March 1, 2015 and March 1, 2017. Subjects will be screened from the patient population at 1960 Family Practice, 837 Cupress Creek Parkway, Suite 105, Houston Texas. Subjects will have presented with a primary complaint of pain. Subjects will be stratified by the following medical indications; Arthritis Muscle Spasms Tendonitis Idiopathic Gout Synovitis Radiculopathy Migraine
Interventions
DRUGbaclofen 2%
compound topical cream
DRUGBupivacaine hydrochloride 1%
compound topical cream
DRUGCyclobenzaprine hydrochloride 2%
compound topical cream
DRUGDiclofenac Sodium 3%
compound topical cream
DRUGFlurbiprofen 10%
compound topical cream
DRUGGabapentin 6%
compound topical cream
DRUGKetamine 10%
compound topical cream
DRUGLidocaine 2%
compound topical cream
DRUGPrilocaine 2.5%
compound topical cream
DRUGMeloxicam 0.09%
compound topical cream
DRUGSumatriptan 5%
compound topical cream
DRUGTizanidine 0.1%
compound topical cream
DRUGTopiramate 2.5%
compound topical cream
DRUGCapsaicin, USP 0.0375%
compound topical cream
DRUGMenthol, NF 5.00 %
compound topical cream
Sponsors
Express Specialty Pharmacy
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* 4.1.1 Primary complaint or clinical findings of arthritis, tendonitis, gout, synovitis, radiculopathy, muscle spasms, migraines, and/or idiopathic pain. 4.1.2 No new pain medications of any kind in the last 4 weeks. 4.1.3 Between the ages of 18-85yrs.
Exclusion criteria
* 4.2.1 Current or history of disease or disorders of the liver, kidneys, gastrointestinal system, or cardiovascular system. 4.2.2 Blood test indicating kidney, liver, or cardiovascular function outside of normal clinically accepted ranges. Blood test must be performed in the last 7 days. 4.2.3 Broken or inflamed skin, burns, open wounds, atopic dermatitis or eczema in the area of pain where the compound cream and transdermal patch would be applied. 4.2.4 Women who are pregnant, nursing, or planning to become pregnant in the next 52-weeks. 4.2.5 Allergy/sensitivity to study drugs or their formulations. 4.2.6 Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. 4.2.7 Serious illness (requiring systemic treatment and/or hospitalization) until subject either completes therapy or is clinically stable on therapy, in the opinion of the site investigator, for at least 14 days prior to study entry. 4.2.8 Inability or unwillingness of subject to give written informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| subjective pain control as measured by a 10-point visual analog scale (VAS). | 24 weeks |
Outcome results
None listed